Good morning, everyone, and welcome to ANI's First Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. It is now my pleasure to turn today's program over to Mr. Arthur Przybyl, President and CEO of ANI Pharmaceuticals. Please go ahead, sir.

Thank you, Tasha. Good morning, everyone. And welcome to ANI's earnings conference call for the first quarter of 2020. My name is Art Przybyl, I'm the CEO. And joining me today is Stephen Carey, our Financial Officer; and Patrick Walsh, an ANI Board Member, who will be stepping in as Interim CEO upon my departure. Before we begin, I want to refer everyone to the forward-looking statements language in this morning's press release and ask each of you to review it carefully as important context for this conference call. Discussions will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles. Reconciliation of those non-GAAP financial measures can be found in our earnings release dated today. ANI reported first quarter 2020 net revenues of $49.8 million, adjusted non-GAAP EBITDA of $17.6 million or 35% of net revenues, and adjusted non-GAAP diluted earnings per share of $1.04. Our first quarter numbers met our internal expectations, and Steve will provide you with additional commentary on our financial results. In January, we closed our acquisition of Amerigen's marketed products and pipeline. The acquisition increased our commercialized generic product portfolio by nine products from 35 to 44. Throughout the first quarter, we launched five generic products, further expanding our generic product offerings to 49 and our total commercialized offerings, including brands, to 60 product families. In March, we filed our prior approval supplement for Cortrophin Gel and received the PDUFA date of July 23, 2020. After that filing, as announced, we received a refusal to file letter from the FDA, and as a result, we will request a Type A meeting with the FDA in order to discuss the deficiencies identified in the refusal to file letter and our plan to address each of them. As you know,…

Thank you, Art, and good morning to everyone on the call. The first quarter of 2020 has marked a period of significant activity at ANI. Throughout the quarter, our team was busy, successfully integrating a sizable generic product acquisition. In March, our Cortrophin development team filed the sNDA for Cortrophin Gel and is currently in the process of requesting a Type A meeting with the FDA to address the deficiencies identified in a recently received Refusal to File letter. And in recent months, our dedicated team of over 300 employees have rallied to continue to serve the public health care system in the midst of the COVID-19 pandemic. During this time, we also say goodbye to our departing President and CEO, Arthur Przybyl, who after leading the growth of ANI over the past 11 years is departing the company effective this Sunday, May 10. On behalf of the Board of Directors, senior management and all employees of ANI, I thank Art for his numerous contributions to the company and wish him well in future endeavors. His legacy is highlighted by the organization he has assembled. And in such, he leaves the company in the hands of a strong management team who remain tirelessly committed to ANI and its stakeholders. Our Board of Directors is currently conducting the search for Art's replacement with Heidrick & Struggles, and in the interim, we welcome Patrick Walsh, a member of our Board to serve as Interim CEO. In January of this year, we acquired the U.S. generic product portfolio of Amerigen Pharmaceuticals for $52.5 million. We separately purchased $4.3 million of inventory, resulting in a total day one consideration of $56.8 million. The U.S. GAAP allocation of purchase price resulted in the capitalization of $45.2 million of product-related intangible assets and $8.4 million of…

Thank you, Steve and Art. I'm delighted to serve as the Interim CEO of the company. And having served as an Independent Director since 2018, I obviously believe in the company's mission and growth objectives. A little bit on my background. My career stands over 35 years in the pharmaceutical industry in a variety of high-growth organizations, including CEO roles in five pharma companies and have served as a director in 12 organizations. In addition to ANI, I currently serve as an independent director for two pharmaceutical businesses, while also serving on a part-time basis as an operating partner at Ampersand capital, a private equity health care organization. My summary bio is outlined in the company's recent filing, and I look forward to working with the leadership team during the executive search process for the new CEO of the company. Finally, I'd like to express my personal thanks to Art for leading the company through an exceptional growth phase, as it allows a new leader to inherit a stable and well positioned business. Art, I'll turn it over to you for closing remarks.

Thank you, Pat, and thank you, Steve. I'd like to thank all of you for attending our conference call today as a continued long-term shareholder I look forward to ANI's continued growth and success. Have a nice morning. Bye-bye.

Thank you, ladies and gentlemen. This does conclude today's conference call. We ask that you now disconnect your line.